Clinical Trial Update: ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors [Phase 1]

View source ↗

Summary

An update on a Phase 1 trial of ACE1702 for advanced or metastatic HER2-expressing solid tumors; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer

Drugs mentioned

• ACE1702

Snippet

Sponsor: Acepodia Biotech, Inc. | Conditions: Locally Advanced Solid Tumor, Metastatic Cancer | Phase 1 | Status: COMPLETED